e-Edition
Obituaries
In Loving Memory
Magazines
Subscribe
Login to Comment
Register
jobs
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Life
Commentary
Contact
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Vertex Pharmaceuticals
(NQ:
VRTX
)
496.83
+16.70 (+3.48%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 27, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,782,951
Open
480.31
Bid (Size)
492.50 (40)
Ask (Size)
496.83 (80)
Prev. Close
480.13
Today's Range
479.75 - 497.80
52wk Range
362.50 - 519.68
Shares Outstanding
259,428,394
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Shows High Technical and Setup Ratings for Potential Breakout
↗
February 28, 2026
Via
Chartmill
2 Top Healthcare Stocks to Buy in February
↗
February 26, 2026
Patience should pay off with these two healthcare giants.
Via
The Motley Fool
Performance
YTD
+9.9%
+9.9%
1 Month
+4.4%
+4.4%
3 Month
+16.7%
+16.7%
6 Month
+23.9%
+23.9%
1 Year
+3.6%
+3.6%
More News
Read More
Forget Centessa Pharmaceuticals: This Rare‑Disease Specialist Has a Superior Portfolio and Pipeline
↗
February 26, 2026
Via
The Motley Fool
Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics
February 25, 2026
Via
MarketMinute
Topics
Intellectual Property
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Posts Mixed Q4 2025 Results, Provides 2026 Guidance
↗
February 12, 2026
Via
Chartmill
2 Nasdaq 100 Stocks Worth Your Attention and 1 We Question
February 24, 2026
Via
StockStory
The Ultimate Biotech Stock to Buy With $500 Right Now
↗
February 24, 2026
Via
The Motley Fool
Topics
Intellectual Property
Could Vertex Stock Help Turn $100,000 Into $1 Million by 2036?
↗
February 22, 2026
Via
The Motley Fool
Topics
Intellectual Property
The Gene‑Therapy Breakthrough Story You'll Be Mad You Ignored at These Prices
↗
February 20, 2026
Via
The Motley Fool
Topics
ETFs
CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows
↗
February 19, 2026
Via
MarketBeat
5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q4 Earnings Call
February 19, 2026
Via
StockStory
Topics
Earnings
1 S&P 500 Stock with Competitive Advantages and 2 We Turn Down
February 18, 2026
Via
StockStory
Topics
Stocks
Vertex: The Quiet Biotech Compounder I'd Happily Hold Through Any Market Crash
↗
February 18, 2026
Via
The Motley Fool
Topics
Artificial Intelligence
Intellectual Property
Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3
February 17, 2026
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Moderna’s mRNA Renaissance: Navigating Volatility and the Post-Pandemic Pipeline
February 17, 2026
Via
Finterra
Topics
Economy
Intellectual Property
Sanofi Tightens Grip on Ocular Therapeutix with Revised Bid as Pivotal SOL-1 Trial Results Loom
February 16, 2026
Via
MarketMinute
Moderna, Vertex Pharmaceuticals, Integra LifeSciences, Baxter, and Molina Healthcare Shares Are Soaring, What You Need To Know
February 13, 2026
Via
StockStory
Topics
Economy
The Blastoff-Ready Biotech Stock You'll Kick Yourself for Not Buying in 2026
↗
February 13, 2026
Via
The Motley Fool
Top S&P500 movers in Friday's session
↗
February 13, 2026
Via
Chartmill
Why CRISPR Therapeutics Stock Is Up Today (Despite Its Q4 Earnings Miss)
↗
February 13, 2026
Via
The Motley Fool
Friday's session: top gainers and losers in the S&P500 index
↗
February 13, 2026
Via
Chartmill
Gilead Sciences and the 2026 Biotech Resurgence: A Leader in the Great Rotation
February 13, 2026
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Government
VRTX Q4 Deep Dive: Diversification Beyond Cystic Fibrosis Sets Stage for Next Growth Phase
February 13, 2026
Via
StockStory
Vertex (VRTX) Q4 2025 Earnings Call Transcript
↗
February 12, 2026
Via
The Motley Fool
Topics
Earnings
Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q4 CY2025: Beats On Revenue
February 12, 2026
Via
StockStory
Frequently Asked Questions
Is Vertex Pharmaceuticals publicly traded?
Yes, Vertex Pharmaceuticals is publicly traded.
What exchange does Vertex Pharmaceuticals trade on?
Vertex Pharmaceuticals trades on the Nasdaq Stock Market
What is the ticker symbol for Vertex Pharmaceuticals?
The ticker symbol for Vertex Pharmaceuticals is VRTX on the Nasdaq Stock Market
What is the current price of Vertex Pharmaceuticals?
The current price of Vertex Pharmaceuticals is 496.83
When was Vertex Pharmaceuticals last traded?
The last trade of Vertex Pharmaceuticals was at 02/27/26 04:00 PM ET
What is the market capitalization of Vertex Pharmaceuticals?
The market capitalization of Vertex Pharmaceuticals is 128.89B
How many shares of Vertex Pharmaceuticals are outstanding?
Vertex Pharmaceuticals has 129B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
wpDiscuz
Insert